Category: Latest News
-
Myriad Genetics shares fall 7.1% after Piper Sandler downgrade
Myriad Genetics (NASDAQ:MYGN) shares fell 7.1% in pre-market trading to $2.99 after Piper Sandler downgraded the stock to “Underweight” from “Overweight” and reduced its price target to $2.00 from $5.45. The brokerage questioned the company’s ability to achieve sustainable profitability through revenue growth or cost reductions alone and identified potential asset divestitures as an alternative…
-
AngloGold Ashanti shares fall 4.9% as gold prices decline
AngloGold Ashanti ADR (NYSE:AU) shares fell 4.9% in pre-market trading to $106.82 as gold prices extended a decline following Federal Reserve Chair Kevin Warsh’s comments at the Jackson Hole symposium. Warsh indicated that while recent inflation data had provided some encouraging signs, it did not demonstrate that underlying inflation trends had improved sufficiently. His comments…
-
Park Hotels & Resorts shares rise 1% after BMO upgrade
Park Hotels & Resorts (NYSE:PK) shares rose 1.0% in pre-market trading to $15.45 after BMO Capital Markets upgraded the lodging REIT to “Outperform” from “Market Perform” and increased its price target to $18 from $14. The new target represents approximately 17.6% upside from the stock’s previous closing price, according to the supplied information. Analyst price…
-
Andersen Group shares rise 3% after Baird raises price target
Andersen Group Corp (NYSE:ANDG) shares rose 3.0% in pre-market trading after Baird increased its price target on the stock to $64 from $57 while maintaining an “Outperform” rating. The analyst action comes ahead of Andersen Group’s next quarterly earnings report, which is scheduled for September 2, 2026. Baird’s $64 price target represents the firm’s assessment…
-
Opus Genetics shares rise 5.9% ahead of OPGx-BEST1 trial data
Opus Genetics Inc (NASDAQ:IRD) shares rose 5.9% in pre-market trading ahead of the scheduled release of three-month topline data from Cohort 1 of its OPGx-BEST1 Phase 1/2 clinical trial. The September 1, 2026 data release concerns OPGx-BEST1, a gene replacement therapy being evaluated in patients with Best Vitelliform Macular Dystrophy and Autosomal-Recessive Bestrophinopathy, two inherited…
-
Ormat Technologies shares rise 3% ahead of dividend payment
Ormat Technologies (NYSE:ORA) shares rose 3.0% in pre-market trading to $105.02 ahead of the geothermal and renewable energy company’s quarterly dividend payment and following its increased full-year revenue guidance. Ormat’s board declared a quarterly dividend of $0.12 per share, payable on September 2, 2026, to shareholders of record as of August 19. As the record…
-
Fractyl Health shares rise 2.8% ahead of Virtual Commercial Strategy Day
Fractyl Health (NASDAQ:GUTS) shares rose 2.8% in pre-market trading ahead of the company’s Virtual Commercial Strategy Day, scheduled for 11:00 AM ET on Tuesday. Management is expected to provide details on the planned commercial strategy and market opportunity for Revita®, the company’s procedural therapy being developed for weight maintenance following discontinuation of GLP-1 treatments. The…
-
Kroger shares fall 1.2% after Citi issues short-term downside watch
Kroger (NYSE:KR) shares fell 1.2% in pre-market trading after Citi placed the supermarket group on a short-term downside Catalyst Watch ahead of its second-quarter 2026 earnings report. Citi expects Kroger to report second-quarter earnings per share of $1.05, in line with the current consensus estimate. However, the firm said it sees an increased likelihood that…
-
Duolingo shares rise 3.8% after Evercore ISI upgrade
Duolingo (NASDAQ:DUOL) shares rose 3.8% in pre-market trading after Evercore ISI analyst Mark Mahaney upgraded the stock to “Outperform” from “In Line” and raised the firm’s price target to $210. Evercore based its revised target on a valuation of 20 times estimated 2028 EBITDA. The firm also increased its earnings forecasts, with its 2027 and…
-
Robinhood Markets shares rise 2.4% after Morgan Stanley upgrade
Robinhood Markets (NASDAQ:HOOD) shares rose 2.4% in pre-market trading after Morgan Stanley upgraded the fintech brokerage to “Overweight” from “Equalweight” and increased its price target to $150 from $124. Morgan Stanley analysts cited evidence that Robinhood’s expanding range of financial products is increasing the value generated from its existing customer base, including higher assets and…